Antibody-drug conjugate
US10973924B2 · kind B2 · utility
6Cited by
18References
2Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 26, 2018 |
| Grant date | Apr 13, 2021 |
| Priority date | — |
| Expiry date | Nov 14, 2038 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02P20/55
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
As an antitumor drug which is excellent in terms of antitumor effect and safety, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an antibody via a linker having a structure represented by the following formula: -L1-L2-LP-NH—(CH2)n1-La-Lb-Lc- wherein the antibody is connected to the terminal of L1, and the antitumor compound is connected to the terminal of Lc with the nitrogen atom of the amino group at position 1 as a connecting position.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.